Jason Walsh

Jason Walsh has a diverse work experience in the biotechnology and pharmaceutical industry. Jason is currently the Managing Director at Monomoy Advisors and the Interim Chief Financial Officer at Carbon Biosciences since 2022. From 2019 to 2022, they served as the Chief Financial Officer at Neutron Therapeutics, Inc., a medical device company specializing in cancer-selective radiotherapy. Prior to that, from 2008 to 2019, Jason held various positions at Provenance Biopharmaceuticals Corp., including Co-founder, Board of Directors, and Chief Business Officer. Jason also worked at Great Brook Biotech from 2010 to 2019 as an outsourced CFO and strategy consultant for life science companies. Jason served as the Director of Business Development at The Forsyth Institute from 2015 to 2017, where they played a key role in launching a start-up incubator and developing corporate partnerships. Jason began their career at Lexigen Pharmaceuticals Corp. in 1993, eventually becoming the Senior Director before the company was acquired by Merck Serono and later Merck KGaA.

Jason Walsh earned an MBA from the Babson F.W. Olin Graduate School of Business, specializing in finance and entrepreneurship, from 2001 to 2003. Prior to that, they obtained a BSBA in management from UMass Boston from 1991 to 1993. Jason began their higher education journey at Champlain College where they earned an AS in entrepreneurship from 1989 to 1991.